Bears Eye KaloBios Pharmaceuticals Inc (KBIO) As Shkreli Gets the Boot

With the shares still halted, KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) boots CEO Martin Shkreli

Dec 21, 2015 at 11:25 AM
facebook twitter linkedin


While shares of KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) remain halted for the third straight day, the company has still landed in the spotlight. The firm just made public that it removed CEO Martin Shkreli on Thursday, following his arrest for securities fraud -- which he blamed on a government witch hunt. The company also announced that Shkreli gave up his spot on the firm's board.

After closing last Thursday at $23.59, KBIO was on the verge of losing half its value before being halted before the open on Friday. When the shares begin trading again, short sellers will be waiting with open arms, as short interest has been increasing steadily on the stock in recent weeks, more than doubling during the past reporting period. 

It's been a wild quarter for the biotech stock. KaloBios Pharmaceuticals Inc was trending lower for over two years, before skyrocketing in November when Shkreli became its largest shareholder and CEO. As such, the stock has added an astonishing 1,135% during the quarter, but could be near single-digit territory once trading resumes. 
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners